Treatment with low doses of tranylcypromine resulted in a disappointing remission rate.

摘要

The article by Patrick J. McGrath, M.D., et al. from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study team (1) reported that treatment with the monoamine oxidase inhibitor (MAOI) tranyicypromine resulted in a 6.9% remission and 12.1% response rate for patients who had not achieved remission in three prior medication trials. These rates are not in accordance with most previous controlled studies on tranyicypromine in refractory depression (some also with patients who failed three prior medication trials), in which response rates up to 50% were found (1-3).